A5029606867- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Heart rate and cardiovascular health
- Heart Rate Variability and Autonomic Control
- Cardiomyopathy and Myosin Studies
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Cardiovascular Effects of Exercise
- Cardiovascular and exercise physiology
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Viral Infections and Immunology Research
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiac, Anesthesia and Surgical Outcomes
- Mechanical Circulatory Support Devices
- Lipoproteins and Cardiovascular Health
- Coronary Interventions and Diagnostics
Maria Cecilia Hospital
2016-2025
Ospedale Maggiore
1979-2025
Nuffield Health
2024
National Health and Medical Research Council
2024
Associazione Nazionale Medici Cardiologi Ospedalieri
2006-2023
Aalborg University
2015-2022
Liverpool Heart and Chest Hospital
2022
University of Liverpool
2022
Centre Hospitalier Universitaire de Tours
2022
Ludwig-Maximilians-Universität München
2021
Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to systolic dysfunction cardiac dyssynchrony. We evaluated its effects on morbidity mortality.Patients New York Heart Association class III or IV dyssynchrony who were receiving standard pharmacologic therapy randomly assigned receive medical alone resynchronization. The primary end point was the time death from any cause an unplanned hospitalization for a major...
In this position statement of the ESC Working Group on Myocardial and Pericardial Diseases an expert consensus group reviews current knowledge clinical presentation, diagnosis treatment myocarditis, proposes new diagnostic criteria for clinically suspected myocarditis its distinct biopsy-proven pathogenetic forms.The aims are to bridge gap between tissue-based diagnosis, improve management provide a common reference point future registries multicentre randomised controlled trials...
In biology, classification systems are used to promote understanding and systematic discussion through the use of logical groups hierarchies. clinical medicine, similar principles standardise nomenclature disease. For more than three decades, heart muscle diseases have been classified into primary or idiopathic myocardial (cardiomyopathies) secondary disorders that morphological appearances, but which caused by an identifiable pathology such as coronary artery disease infiltration (specific...
Guidelines and Expert Consensus Documents aim to present all the relevant evidence on a particular issue in order help physicians weigh benefits risks of diagnostic or therapeutic procedure.They should be helpful everyday clinical decision-making.A great number have been issued recent years by European Society Cardiology (ESC) different organizations other related societies.This profusion can put at stake authority validity guidelines, which only guaranteed if they developed an...
Background— Data from single-center studies suggest that echocardiographic parameters of mechanical dyssynchrony may improve patient selection for cardiac resynchronization therapy (CRT). In a prospective, multicenter setting, the Predictors Response to CRT (PROSPECT) study tested performance these predict response. Methods and Results— Fifty-three centers in Europe, Hong Kong, United States enrolled 498 patients with standard indications (New York Heart Association class III or IV heart...
Aims Large randomized trials have shown that beta-blockers reduce mortality and hospital admissions in patients with heart failure. The effects of elderly a broad range left ventricular ejection fraction are uncertain. SENIORS study was performed to assess the beta-blocker, nebivolol, ≥70 years, regardless fraction.
Background — Our purpose was to assess the time course of benefit n-3 polyunsaturated fatty acids (PUFAs) on mortality documented by GISSI-Prevenzione trial in patients surviving a recent (<3 months) myocardial infarction. Methods and Results In this study, 11 323 were randomly assigned supplements PUFAs, vitamin E (300 mg/d), both, or no treatment (control) top optimal pharmacological lifestyle advice. Intention-to-treat analysis adjusted for interaction between treatments carried out....
The objective of the EuroHeart Failure Survey II (EHFS II) was to assess patient characteristics, aetiology, treatment, and outcome acute heart failure (AHF) in Europe relation guidelines on diagnosis treatment AHF published by European Society Cardiology.Patients hospitalized for were recruited 133 centres 30 countries. Three thousand five hundred eighty patients entered into database end August 2005. Mean age 70 years, 61% male. New-onset (de novo AHF) diagnosed 37%, which 42% due coronary...
Background— Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept heart failure. Methods Results— Patients with New York Heart Association class II to IV chronic failure left ventricular ejection fraction ≤0.30 were enrolled 2 trials that differed only doses of used. In RECOVER, patients received placebo (n=373) or subcutaneous 25 mg every week (n=375) twice per (n=375)....
The aim of this study was to evaluate the benefits and safety long-term i.v. iron therapy in iron-deficient patients with heart failure (HF). CONFIRM-HF a multi-centre, double-blind, placebo-controlled trial that enrolled 304 ambulatory symptomatic HF left ventricular ejection fraction ≤45%, elevated natriuretic peptides, deficiency (ferritin <100 ng/mL or 100–300 if transferrin saturation <20%). Patients were randomized 1 : treatment iron, as ferric carboxymaltose (FCM, n = 152) placebo...
Abstract Aims The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in burden and healthcare delivery together estimates progress towards meeting 2025 World Health Organization (WHO) non-communicable targets. Methods results In this report, CVD are presented for countries ESC. drawn ESC which is repository data variety...
The CArdiac REsynchronization-Heart Failure study randomized patients with left ventricular ejection fraction < or =35%, markers of cardiac dyssynchrony, and persistent moderate severe symptoms heart failure despite pharmacological therapy, to implantation a resynchronization therapy (CRT) device not. main observed substantial benefits on morbidity mortality during mean follow-up 29.4 months [median 29.6, interquartile range (IQR) 23.6-34.6]. Prior closure, an extension phase lasting further...